Immunotherapy of Crohn's disease

Autor: C. van Montfrans, L. Camoglio, S. J. H. van Deventer

Publikováno v: Mediators of Inflammation, Vol 7, Iss 3, Pp 149-152 (1998)

Although the initiating events of Crohn's disease are unknown, models of experimental colitis have provided new insights in the immunologically mediated pathways of mucosal inflammation. In Crohn's disease activated mucosal T lymphocytes produce proi

Externí odkaz: https://doaj.org/article/9ead3554de6c497f87deaf2ddd1d91ea

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

A systematic review on the role of imiquimod in lentigo maligna and lentigo maligna melanoma: need for standardization of treatment schedule and outcome measures

Autor: J van der Woude, C A C Prinsen, Darryl Tio, R Hoekzema, C. Van Montfrans, Elise P. Jansma

Publikováno v: Tio, D, van der Woude, J, Prinsen, C A C, Jansma, E P, Hoekzema, R & van Montfrans, C 2017, ' A systematic review on the role of imiquimod in lentigo maligna and lentigo maligna melanoma : need for standardization of treatment schedule and outcome measures ', Journal of the European Academy of Dermatology and Venereology, vol. 31, no. 4, pp. 616-624 . https://doi.org/10.1111/jdv.14085
Tio, D, van der Woude, J, Prinsen, C A C, Jansma, E P, Hoekzema, R & van Montfrans, C 2016, ' A systematic review on the role of imiquimod in lentigo maligna and lentigo maligna melanoma : need for standardization of treatment schedule and outcome measures ', JEADV. Journal of the European Academy of Dermatology and Venereology . https://doi.org/10.1111/jdv.14085
Journal of the European Academy of Dermatology and Venereology, 31(4), 616-624. Wiley-Blackwell
JEADV. Journal of the European Academy of Dermatology and Venereology. Wiley-Blackwell

BACKGROUND: Lentigo maligna (LM) is an in situ variant of melanoma. Our objective was to systematically review clinical and histological clearance and recurrence rates of imiquimod treatment of LM with emphasis on progression to lentigo maligna melan

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2354f7b04a8817af69a1623c15fd293d
https://pure.eur.nl/en/publications/76c7c6b7-8971-48cb-b387-2e04228c07c4

Variation in the diagnosis and clinical management of lentigo maligna across Europe: a survey study among European Association of Dermatologists and Venereologists members

Autor: Matthias Augustin, Darryl Tio, C. Van Montfrans, Brigitte Dréno, Cecilia A.C. Prinsen, R. Hoekzema

Publikováno v: Journal of the Academy of Dermatology and Venereology, 32(9), 1476-1484. Wiley-Blackwell
Tio, D, Prinsen, C A C, Dréno, B, Hoekzema, R, Augustin, M & van Montfrans, C 2018, ' Variation in the diagnosis and clinical management of lentigo maligna across Europe: a survey study among European Association of Dermatologists and Venereologists members ', Journal of the European Academy of Dermatology and Venereology, vol. 32, no. 9, pp. 1476-1484 . https://doi.org/10.1111/jdv.14850
Journal of the European Academy of Dermatology and Venereology, 32(9), 1476-1484. Wiley-Blackwell

Background: Lentigo maligna (LM), a form of melanoma in situ, is treated to prevent progression to lentigo maligna melanoma (LMM). Surgical treatment is the gold standard. However, treatment guidelines are based on expert opinion, and comparative stu

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::990e11bf63a9062c71840b047265b959
https://pure.eur.nl/en/publications/b830ef6f-4029-4780-a982-151aadc23fb3